BR112017011552A2 - derivados de fgf21 e seu uso - Google Patents

derivados de fgf21 e seu uso

Info

Publication number
BR112017011552A2
BR112017011552A2 BR112017011552-2A BR112017011552A BR112017011552A2 BR 112017011552 A2 BR112017011552 A2 BR 112017011552A2 BR 112017011552 A BR112017011552 A BR 112017011552A BR 112017011552 A2 BR112017011552 A2 BR 112017011552A2
Authority
BR
Brazil
Prior art keywords
derivatives
fgf21
fgf21 derivatives
relates
cysteine
Prior art date
Application number
BR112017011552-2A
Other languages
English (en)
Inventor
Wieczorek Birgit
Møller Tagmose Tina
Sass-Ørum Kristian
Andersen Birgitte
Olsen Jørgen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of BR112017011552A2 publication Critical patent/BR112017011552A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a um derivado de uma proteína do fgf21 tendo um resíduo de cisteína em uma posição que corresponde à posição 167, 169, 170, 171, 172, 173, 174, 175 e em particular a posição 180 ou posição 181 do fgf21 humano maduro e seus derivados tendo uma cadeia lateral ligada à esta cisteína. os derivados de fgf21 da invenção apresentam alta potência para os receptores do fgf. a invenção também refere-se às composições farmacêuticas que compreendem tais derivados de fgf21 e excipientes farmaceuticamente aceitáveis, assim como o uso médico dos derivados de fgf21.
BR112017011552-2A 2014-12-23 2015-12-22 derivados de fgf21 e seu uso BR112017011552A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935.9 2014-12-23
EP14199935 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (1)

Publication Number Publication Date
BR112017011552A2 true BR112017011552A2 (pt) 2018-02-14

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011552-2A BR112017011552A2 (pt) 2014-12-23 2015-12-22 derivados de fgf21 e seu uso

Country Status (26)

Country Link
US (3) US9744213B2 (pt)
EP (1) EP3236991B1 (pt)
JP (1) JP6727210B2 (pt)
KR (1) KR102427527B1 (pt)
CN (1) CN107108709B (pt)
AR (1) AR103246A1 (pt)
AU (1) AU2015371056B2 (pt)
BR (1) BR112017011552A2 (pt)
CA (1) CA2972128A1 (pt)
DK (1) DK3236991T3 (pt)
ES (1) ES2742503T3 (pt)
HK (1) HK1246156B (pt)
HR (1) HRP20191292T1 (pt)
HU (1) HUE044783T2 (pt)
IL (1) IL252438B (pt)
MX (1) MX2017007458A (pt)
MY (1) MY181181A (pt)
PL (1) PL3236991T3 (pt)
PT (1) PT3236991T (pt)
RS (1) RS59154B1 (pt)
RU (1) RU2729011C2 (pt)
SA (1) SA517381673B1 (pt)
SI (1) SI3236991T1 (pt)
TW (2) TWI708781B (pt)
WO (1) WO2016102562A1 (pt)
ZA (1) ZA201703768B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
CN114601932A (zh) * 2017-09-04 2022-06-10 89生物有限公司 突变型fgf-21肽缀合物及其用途
MX2021000016A (es) 2018-07-03 2021-03-09 Bristol Myers Squibb Co Formulaciones de factor de crecimiento de fibroblastos (fgf-21).
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
WO2022238503A1 (en) 2021-05-11 2022-11-17 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
WO2024008904A2 (en) 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
US7452966B2 (en) 2003-06-12 2008-11-18 Eli Lilly And Company GLP-1 analog fusion proteins
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005028516A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
BRPI0416683A (pt) 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
WO2005091944A2 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
PL1751184T3 (pl) 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
JP2008507477A (ja) 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
SI1789442T1 (sl) 2004-09-02 2010-01-29 Lilly Co Eli Proteinske mutante fibroblastnega rastnega faktorja 21
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006065582A2 (en) 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
SI2068909T1 (sl) 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
ES2646614T3 (es) 2007-08-03 2017-12-14 Eli Lilly And Company Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
NZ592009A (en) 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
US9480753B2 (en) * 2009-01-23 2016-11-01 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
SI3248610T1 (sl) 2009-05-05 2024-03-29 Amgen Inc., Mutanti fgf21 in njihove uporabe
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2010142665A1 (en) 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
WO2012010553A1 (en) * 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
WO2013033452A2 (en) * 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
SG11201500682WA (en) * 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
KR20150104579A (ko) * 2012-12-27 2015-09-15 엔지엠 바이오파마슈티컬스, 아이엔씨. 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법

Also Published As

Publication number Publication date
RS59154B1 (sr) 2019-10-31
KR20170095256A (ko) 2017-08-22
CN107108709A (zh) 2017-08-29
AU2015371056A1 (en) 2017-06-15
CN107108709B (zh) 2021-12-14
HK1246156B (zh) 2020-03-27
EP3236991B1 (en) 2019-06-19
US20170354713A1 (en) 2017-12-14
WO2016102562A1 (en) 2016-06-30
TWI681966B (zh) 2020-01-11
TW202012431A (zh) 2020-04-01
US9744213B2 (en) 2017-08-29
RU2729011C2 (ru) 2020-08-03
IL252438A0 (en) 2017-07-31
US10124039B2 (en) 2018-11-13
JP6727210B2 (ja) 2020-07-22
US9895417B2 (en) 2018-02-20
MX2017007458A (es) 2017-08-10
MY181181A (en) 2020-12-21
US20180140673A1 (en) 2018-05-24
ZA201703768B (en) 2020-05-27
ES2742503T3 (es) 2020-02-14
SI3236991T1 (sl) 2019-09-30
PL3236991T3 (pl) 2019-12-31
CA2972128A1 (en) 2016-06-30
IL252438B (en) 2021-09-30
KR102427527B1 (ko) 2022-08-01
RU2017125050A (ru) 2019-01-25
AU2015371056B2 (en) 2020-06-25
RU2017125050A3 (pt) 2019-06-06
TW201632545A (zh) 2016-09-16
JP2018505146A (ja) 2018-02-22
TWI708781B (zh) 2020-11-01
PT3236991T (pt) 2019-09-06
HRP20191292T1 (hr) 2019-10-18
HUE044783T2 (hu) 2019-11-28
SA517381673B1 (ar) 2020-10-29
DK3236991T3 (da) 2019-08-26
US20170182124A1 (en) 2017-06-29
AR103246A1 (es) 2017-04-26
EP3236991A1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
BR112017011552A2 (pt) derivados de fgf21 e seu uso
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112016008016A2 (pt) inibidores de kras g12c
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112016029848A2 (pt) proteínas de fusão mic-1 e utilizações das mesmas
BR112015018087A8 (pt) composto, composição farmacêutica e uso
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
NI201900119A (es) Derivados de indolina sustitudos como inhibidores de la replicación vírica de dengue
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112018003877A2 (pt) “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
BR112017020948A2 (pt) composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112018003455A2 (pt) composição ou composição farmacêutica e uso da composição
ECSP21002804A (es) Apirasas solubilizadas, métodos y usos
BR112012015386B8 (pt) composição oftálmica tópica
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112017013998A2 (pt) novos derivados de benzimidazol como agentes anti-histamínicos
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]